Komori
Other Disclosures4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Received the Japan Society for Biomaterials Award for the commercialization of high-purity alginate gel for cartilage regeneration therapy

Mochida Pharmaceutical's commercialization of cartilage regeneration therapy using high-purity alginate gel was recognized, and company representatives and others received the Japan Society for Biomaterials Award (Technology and Clinical). The product received manufacturing and marketing approval in Japan in July 2025 and was launched in December of the same year.

Worth reading
60In focus
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Cartilage repair material, MochiGelHigh-purity alginate gel
Applicable field (uses covered by this announcement)

Cartilage regeneration therapy, cartilage repair

Launch dateDecember 2025 (sales launch, actual)
Relationship between the counterparty and the company
Mochida Pharmaceutical Co.,Ltd.4534
Relationship with the Company

Mochida Pharmaceutical has worked on the research and development, product development and commercialization. Professor Iwasaki Norimasa (岩崎倫政) of the Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, participated in the research.

CounterpartyJapan Society for Biomaterials

A society that presents awards for biomaterials science and technology, including biomedical engineering and medical device development technology. Other details: Not disclosed.

Award/certification name

Japan Society for Biomaterials Award (Technology and Clinical)

Awarding / certifying body

Japan Society for Biomaterials

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredCartilage repair material, MochiGel, High-purity alginate gel
CounterpartyJapan Society for Biomaterials
Counterparty overviewA society that presents awards for biomaterials science and technology, including biomedical engineering and medical device development technology. Other details: Not disclosed.
Relationship with the CompanyMochida Pharmaceutical has worked on the research and development, product development and commercialization. Professor Iwasaki Norimasa (岩崎倫政) of the Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, participated in the research.
Launch dateDecember 2025 (sales launch, actual)
Applicable areaCartilage regeneration therapy, cartilage repair
Award/certification nameJapan Society for Biomaterials Award (Technology and Clinical)
Awarding / certifying bodyJapan Society for Biomaterials
Items this document does not state (10)
Contract ValueOffering priceContract DateRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The award recognized a series of achievements that brought many years of research and development on cartilage regeneration therapy using high-purity alginate gel through to commercialization and practical application.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Received the Japan Society for Biomaterials Award for the commercialization of high-purity alginate gel for cartilage regeneration therapy | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori